Galicia-Carmona Tatiana, Arango-Bravo Eder Alexandro, Coronel-Martínez Jaime A, Cetina-Pérez Lucely, Vanoye-Carlo Elva G, Villalobos-Valencia Ricardo, García-Pacheco José A, Cortés-Esteban Patricia
Department of Clinical Research, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Department of Medical Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Front Oncol. 2024 Aug 5;14:1392639. doi: 10.3389/fonc.2024.1392639. eCollection 2024.
Cervical cancer constitutes a significant health burden for women worldwide despite being preventable by vaccination and screening. Advanced stages of the disease are associated with a poor prognosis, and treatment approaches have seen little change over several decades, resulting in an overall survival rate of no more than 17 months. Additionally, there are limited options for second-line treatment. The urgent need for innovative and effective therapies to improve the outlook for this group of patients, along with an enhanced understanding of the interactions between the disease and the host's immune system, has propelled immunotherapy into a rapidly advancing field with notable achievements. Among various immunotherapeutic approaches, immune checkpoint inhibitors emerge as the most advanced treatment option. Clinical trials assessing these inhibitors as single agents or in combination with chemotherapy show promising results. As immunotherapy begins to redefine standards of care for metastatic, recurrent, or persistent cervical cancer, this review addresses recent advances and current recommendations for its management in both first and second-line treatment. The goal is to provide insights into the evolving landscape of cervical cancer treatment, specifically focusing on immunotherapeutic interventions.
尽管宫颈癌可通过疫苗接种和筛查预防，但它仍是全球女性面临的重大健康负担。该疾病的晚期预后较差，且几十年来治疗方法变化不大，总体生存率不超过17个月。此外，二线治疗选择有限。迫切需要创新有效的疗法来改善这类患者的预后，同时对疾病与宿主免疫系统之间相互作用的深入理解，推动免疫疗法成为一个迅速发展且取得显著成果的领域。在各种免疫治疗方法中，免疫检查点抑制剂成为最先进的治疗选择。评估这些抑制剂作为单一药物或与化疗联合使用的临床试验显示出有前景的结果。随着免疫疗法开始重新定义转移性、复发性或持续性宫颈癌的治疗标准，本综述阐述了其在一线和二线治疗管理方面的最新进展和当前建议。目的是深入了解宫颈癌治疗的不断变化的格局，特别关注免疫治疗干预措施。
